title: Serum CA125 level predicts prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy.
abstract: This study was to evaluate the effect of serum CA125 level on the prognosis of patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy. Sixty-six patients with multiple brain metastases from non-small cell lung cancer before and after treatment of radiotherapy were reviewed retrospectively. Radiotherapy was given to the whole brain using opposed 6MV lateral beams with a dose of 30 Gy in 15 fractions in 3 weeks. Elevated CA125 was defined as >35 U/mL. The survival rate was calculated using the Kaplan-Meier method, and the univariate and multivariate analyses were used to identify significant factors associated with prognosis, using a Cox proportional hazards model. During the median (range) follow-up of 1.25 (0.25-2.50) years, 62 patients died from non-small cell lung cancer; the 1-year cancer-specific survival (CSS) rate was 43.08 %. Thirty patients had a high CA125 level before chemoradiotherapy (>35U/mL), and their CSS rate was significantly worse than that in the remaining patients (P = 0.024). Multivariate analysis showed that CA125 level, number of metastases and total tumor volume were independent prognostic indicators for CSS, with a hazard ratio of 1.99, 1.67 and 2.02, respectively. The elevation of CA125 before treatment predicts a poor prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy.
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Shenyang, 110022, China, wellyy2005@hotmail.com.
authors.forename: Yue-Can
authors.initials: YC
authors.lastname: Zeng
authors.forename: Rong
authors.initials: R
authors.lastname: Wu
authors.forename: Si-Liang
authors.initials: SL
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Chi
authors.forename: Rui
authors.initials: R
authors.lastname: Xing
authors.forename: Wei-Song
authors.initials: WS
authors.lastname: Cai
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Fan
authors.forename: Yu-Chen
authors.initials: YC
authors.lastname: Fan
authors.forename: Wen-Zhao
authors.initials: WZ
authors.lastname: Zhong
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Wu
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Chen
authors.forename: Huan-Huan
authors.initials: HH
authors.lastname: Chen
authors.forename: Yu-Ping
authors.initials: YP
authors.lastname: Xiao
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D018394:CA-125 Antigen / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D015996:Survival Rate; D047368:Tumor Burden
chemical_list: D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins